Gilead Details Strong Sovaldi Launch, Plans HCV Combo Pill Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Less than one month after U.S. approval, the HCV drug has posted sales of $139 million, with about 70% of use occurring in patients carrying genotype 1 of the virus. Gilead reported 21% sales growth for the fourth quarter of 2013, 15% for the full year.